Update protocol chemotherapy of malignant neoplasms of the pancreas MRK003 new experimental drug has shown good results in laboratory and clinical studies.
The combination is usually used in such cases, the anticancer drug gemcitabine with MRK003 led to a significant reduction of tumors and prolonged the life of mice with artificially induced pancreatic cancer.
The study of the effectiveness of an experimental drug MRK003 conducted by British scientists at Cambridge University.
MRK003 has the ability not only to stop the growth and division of tumor cells, but also block the development of endothelial tissue that lines the inside blood vessels that feed tumors.
Using a combination of gemcitabine with MRK003 showed efficacy in phase I clinical trials involving more patients suffering from metastatic adenocarcinoma of the pancreas.
In the near future will begin the second phase of clinical trials MRK003, which would have involved 60 patients with this kind of cancer.
Study leader Professor Duncan Jodrell from Cambridge explains
We are very satisfied with the preliminary tests of an experimental drug MRK003. Although definitive conclusions about its effectiveness is still necessary to conduct several clinical trials, we believe that some time later MRK003 can replenish the arsenal of oncologists